Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes.
Fixed-ratio combination
GLP-1 RA
Glycemic control
Insulin therapy
Type 2 diabetes
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
19
10
2020
accepted:
19
12
2020
pubmed:
24
2
2021
medline:
20
4
2021
entrez:
23
2
2021
Statut:
ppublish
Résumé
Treatment of type 2 diabetes (T2D) requires progressive therapy intensification to reach and maintain individualized glycemic targets. iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL (iGlar) and lixisenatide (Lixi), has been shown to provide robust HbA
Identifiants
pubmed: 33620694
doi: 10.1007/s12325-020-01614-5
pii: 10.1007/s12325-020-01614-5
pmc: PMC8004501
doi:
Substances chimiques
Drug Combinations
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
Insulin Glargine
2ZM8CX04RZ
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Pagination
1715-1731Références
Diabetes Care. 2016 Aug;39(8):1318-28
pubmed: 27222510
Diabet Med. 2006 Jul;23(7):750-6
pubmed: 16842479
Diabetes Care. 2018 Dec;41(12):2669-2701
pubmed: 30291106
Diabetes Obes Metab. 2018 Sep;20(9):2314-2318
pubmed: 29785837
Diabetes Obes Metab. 2019 Aug;21(8):1967-1972
pubmed: 31124299
Diabetes Obes Metab. 2019 Feb;21(2):321-329
pubmed: 30520217
Diabetes Obes Metab. 2017 Dec;19(12):1798-1804
pubmed: 28432746
Diabetes Care. 2019 Nov;42(11):2108-2116
pubmed: 31530665
Diabetes Metab Res Rev. 2015 Feb;31(2):204-11
pubmed: 25115916
Lancet Diabetes Endocrinol. 2014 Nov;2(11):885-93
pubmed: 25190523
Diabetes Ther. 2020 Jan;11(1):305-318
pubmed: 31848983
QJM. 2003 Apr;96(4):281-8
pubmed: 12651972
BMJ. 2000 Aug 12;321(7258):405-12
pubmed: 10938048
Diabetes Obes Metab. 2020 Dec;22(12):2295-2304
pubmed: 32729183
Diabetes Care. 2016 Nov;39(11):2026-2035
pubmed: 27527848
Diabetes Care. 2013 Sep;36(9):2497-503
pubmed: 23564915
Diabetes Metab Res Rev. 2017 Mar;33(3):
pubmed: 27606888
Diabetes Ther. 2018 Feb;9(1):373-382
pubmed: 29143919
Diabetes Ther. 2019 Oct;10(5):1645-1717
pubmed: 31359367
Diabetes Care. 2014 Nov;37(11):2926-33
pubmed: 25114296
Clin Diabetes. 2018 Apr;36(2):174-182
pubmed: 29686457
Diabetes Ther. 2018 Jun;9(3):1347-1358
pubmed: 29600507
Diabetes Obes Metab. 2020 Sep;22(9):1683-1689
pubmed: 32363634
Diabetes Ther. 2020 Nov;11(11):2629-2645
pubmed: 32902774
Diabetes Ther. 2020 Apr;11(4):1007-1015
pubmed: 32166620
JAMA. 2019 Jan 1;321(1):69-79
pubmed: 30418475
Diabetes Spectr. 2018 May;31(2):145-154
pubmed: 29773934
Nat Rev Endocrinol. 2012 Dec;8(12):728-42
pubmed: 22945360
Diabetes Obes Metab. 2018 Dec;20(12):2821-2829
pubmed: 29974618
Expert Opin Drug Discov. 2014 Oct;9(10):1223-51
pubmed: 25119443
Diabetes Care. 2020 Jan;43(Suppl 1):S1-S2
pubmed: 31862741
Diabetes Care. 2016 Nov;39(11):1972-1980
pubmed: 27650977
Diabetes Obes Metab. 2017 Oct;19(10):1408-1415
pubmed: 28386990
N Engl J Med. 2018 Aug 16;379(7):633-644
pubmed: 30110583
Mol Aspects Med. 2015 Dec;46:21-33
pubmed: 26549348
N Engl J Med. 2008 Oct 9;359(15):1577-89
pubmed: 18784090
Diabetes Ther. 2017 Oct;8(5):1097-1109
pubmed: 28921256